Since I've received so many positive reader emails about my first installment on biotech investing, I've put together another list of biotech companies that are expected to report major upcoming catalysts in the form of clinical trial data and FDA decisions. Just as I did before, I have put together a list of companies that are expected to be on the move within the next nine months and have a market cap ranging from around $100 million to just beyond $1 billion. Let's get right to it.
Keep in mind that this story is not meant to serve as an exhaustive list of all companies in the sector. I purposely excluded the biggest and best-known biotech and big pharma companies. Once again, my goal is to provide readers with a selection of companies that offer good leverage, as a result of their smaller size, and have a major shakeup in the works. We should see some interesting developments from these companies in the weeks to come.
Looking for more Foolish biotech coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all of our recommendations, and get access to our message boards and exclusive content, with a 30-day free trial.
Fool contributor Mike Havrilla, R.Ph., B.S., Pharm.D., is a Rite Aid pharmacist who lives and works in the small Pennsylvania town of Portage. He invites your comments and feedback. Mike does not have a position in any company mentioned in this article. The Fool has a disclosure policy.